Login
$RXST
$5.29 -$0.01 (0.19%) After hours

$RXST 8-K SEC Filings

Filed On Filing
03 Nov 2026 8-K: Results of Operations and Financial Condition

Aliso Viejo, Calif. – November 3, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended September 30, 2026.

05 Aug 2026 8-K: Results of Operations and Financial Condition

Aliso Viejo, Calif. – August 5, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook.

15 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Aliso Viejo, Calif. – July 15, 2026 – RxSight, Inc. (NASDAQ: RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., ...

06 Jul 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

Non-exclusive license agreement for the development and commercialization of novel post-operative light adjustable PCIOL technologies

06 Jul 2026 8-K: Results of Operations and Financial Condition

RXSIGHT, INC. ANNOUNCES PRELIMINARY SECOND QUARTER FINANCIAL RESULTS AND PRODUCT PIPELINE UPDATES FOLLOWING STRATEGIC COLLABORATION AGREEMENT

16 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

We held our 2026 Annual Meeting of Stockholders (“Annual Meeting”) on June 16, 2026. Of the 41,396,609 shares of our common stock outstanding as of April 21, 2026, 33,299,192 shares of common stock were represented, either by attending t...

06 May 2026 8-K: Results of Operations and Financial Condition

Aliso Viejo, Calif. – May 6, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended March 31, 2026.

25 Feb 2026 8-K: Results of Operations and Financial Condition

Aliso Viejo, Calif. – February 25, 2026 – RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter and full year ended December 31, 2025.

12 Jan 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more

Aliso Viejo, Calif. (Nasdaq: RXST) – January 11, 2026 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary...

23 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

In connection with the previously announced pending transition of Shelley Thunen from her position as the Company’s Chief Financial Officer (and principal financial and accounting officer), on December 23, 2025, RxSight, Inc. (the “Compa...

22 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Aliso Viejo, Calif. (Nasdaq: RXST) – December 22, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that Shelley Thune...

19 Dec 2025 8-K: Departure/Election of Directors or Officers; Compensation

On December 18, 2025, the Board of Directors (the “Board”) of RxSight, Inc. (the “Company”) appointed Eric Weinberg to the executive officer position of Chief Business Development Officer concurrent with his transition from the Chief Com...

05 Nov 2025 8-K: Results of Operations and Financial Condition

Aliso Viejo, Calif. (Nasdaq: RXST) – November 5, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results fo...

07 Aug 2025 8-K: Results of Operations and Financial Condition

Aliso Viejo, Calif. (Nasdaq: RXST) – August 7, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for ...

04 Aug 2025 8-K: Departure/Election of Directors or Officers; Compensation

Aliso Viejo, Calif., (Nasdaq: RXST) August 4, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced the appointment of Ray...

08 Jul 2025 8-K: Results of Operations and Financial Condition

Aliso Viejo, Calif. (NASDAQ: RXST) – July 8, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary fina...

04 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

We held our 2025 Annual Meeting of Stockholders (“Annual Meeting”) on June 3, 2025. Of the 40,620,239 shares of our common stock outstanding as of April 8, 2025, 32,181,609 shares of common stock were represented, either by attending the...

07 May 2025 8-K: Results of Operations and Financial Condition

Aliso Viejo, Calif. (NASDAQ: RXST) – May 7, 2025– RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the ...

03 Apr 2025 8-K: Results of Operations and Financial Condition

Aliso Viejo, Calif. (NASDAQ: RXST) – April 2, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary rev...

25 Feb 2025 8-K: Results of Operations and Financial Condition

Aliso Viejo, Calif. (NASDAQ: RXST) – February 25, 2025 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced financial results ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support